Escitalopram co-prescription in anastrozole-treated breast cancer patients

CONCLUSION: Escitalopram co-prescription resulted in significant increase in plasma anastrozole levels without affecting the serum estradiol levels. Our findings emphasize the need for close monitoring in case of concomitant use of anastrozole and escitalopram, especially in obese patients and the potential role of therapeutic drug monitoring.PMID:36199859 | PMC:PMC9464843 | DOI:10.14744/nci.2022.48264

Source: Clinical Breast Cancer - October 6, 2022 Category: Cancer & Oncology Authors: Hazan Ozyurt Sevgi Ozden Cengiz Gemici Esra Kucukibrahimoglu Hatice Odabas Neset Nesetoglu Durisehvar Unal Pinar Uler Gokhan Yaprak Huseyin Tepetam Mahmut Gumus Mehmet Zafer Goren Source Type: research